Update on transcatheter aortic valve replacement.

Transcatheter aortic valve replacement (TAVR) is currently the treatment modality of choice for patients with symptomatic severe aortic stenosis who are inoperable or at high risk for surgical aortic valve replacement. TAVR has shown a clear mortality benefit compared to conservative treatment in inoperable patients and is at least non-inferior to surgical aortic valve replacement in high-risk operable patients. Through improvements in pre-procedural imaging, refinement in valve technologies, increasing operator and team experience, and continuous valuable research, TAVR has developed rapidly in the past few years and is expected to further boost in the near future. In this review, we highlight the current status of TAVR, summarize recent updates, and discuss briefly the future expectations of this rapidly evolving technology.